Patents by Inventor Kazutake Tsujikawa

Kazutake Tsujikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220178932
    Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).
    Type: Application
    Filed: April 15, 2020
    Publication date: June 9, 2022
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY, TOSOH CORPORATION
    Inventors: Koji UEDA, Naomi OHNISHI, Kazutake TSUJIKAWA, Norio NONOMURA, Motohide UEMURA, Kentaro JINGUSHI, Norihisa OHTAKE, Yasutoshi KAWAI
  • Publication number: 20190310258
    Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.
    Type: Application
    Filed: October 26, 2017
    Publication date: October 10, 2019
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY
    Inventors: Koji Ueda, Naomi Ohnishi, Norio Nonomura, Motohide Uemura, Kazutoshi Fujita, Kazutake Tsujikawa, Kentarou Jingushi
  • Patent number: 9212169
    Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: December 15, 2015
    Assignees: HYOGO COLLEGE OF MEDICINE, KAGOSHIMA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Kazutake Tsujikawa, Akito Tanaka, Shunji Aoki, Hiroaki Mizuno, Miyuki Tokoro, Tatsuhiko Furukawa
  • Publication number: 20150011600
    Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 8, 2015
    Inventors: Kazutake Tsujikawa, Akito Tanaka, Shunji Aoki, Hiroaki Mizuno, Miyuki Tokoro, Tatsuhiko Furukawa
  • Publication number: 20100297145
    Abstract: Disclosed is an apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer or the like which comprises a compound capable of inhibit the expression or function of PCA-1 as an active ingredient. Also disclosed is a method for screening of a compound for use in the promotion of apoptosis, the inhibition of cell proliferation or the prevention/treatment of cancer, which comprises selecting a compound capable of inhibit the expression or function of PCA-1, or the like.
    Type: Application
    Filed: August 4, 2006
    Publication date: November 25, 2010
    Inventors: Kazutake Tsujikawa, Hiroshi Yamamoto, Noboru Konishi
  • Publication number: 20090130662
    Abstract: The present invention provides a method for detecting and/or quantifying PCA-1 in a body fluid sample from a subject as a prostate cancer marker. The present invention also provides a method for detecting and/or quantifying an anti-PCA-1 autoantibody in a body fluid sample from a subject as a prostate cancer marker. The present invention allows diagnosis of prostate cancer to be performed more simply, more rapidly and at lower cost.
    Type: Application
    Filed: March 14, 2006
    Publication date: May 21, 2009
    Inventors: Kazutake Tsujikawa, Hiroshi Yamamoto, Noboru Konishi
  • Patent number: 7358061
    Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: April 15, 2008
    Assignee: Fuso PHarmaceutical Industries, Ltd.
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi
  • Publication number: 20080020375
    Abstract: The present invention relates to a method for determining a subject having a risk of having developed or developing prostate cancer, which comprises the following steps: a) a step of analyzing the presence/absence or level of mutation in the PCA-1 gene derived from the subject; and b) a step of evaluating the presence/absence or level of the subject's risk of having developed or developing prostate cancer, based on the presence/absence or level of mutation in the PCA-1 gene. According to the determination method of prostate cancer of the present invention, a subject having a risk of having developed or developing prostate cancer can be determined conveniently and highly sensitively. Therefore, the method is effective for the diagnosis of prostate cancer, progress monitoring, prognostic prediction, diagnosis before the onset, carrier diagnosis and the like.
    Type: Application
    Filed: August 24, 2004
    Publication date: January 24, 2008
    Inventors: Hiroshi Yamamoto, Noboru Konishi, Kazutake Tsujikawa
  • Patent number: 6933135
    Abstract: Antibodies to intracellular domains of two or more kinds of protein tyrosine phosphatases, methods for generation thereof and cells producing these antibodies are disclosed. The antibody of the present invention may have specificity to intracellular domains of phosphatase subunits of both of LAR and CD45, and may be useful for analysis and quantitative determination of PTPs, identification and detection of novel PTPs, and for obtaining novel phosphatases by cloning and the like, as well as for developing useful diagnostic methods of insulin resistance and NIDDM, for prophylaxis and diagnosis of various disease states of syndrome X that is based on insulin resistance, and for prophylaxis and diagnosis of onsets of arteriosclerosis and cardiac diseases.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: August 23, 2005
    Assignee: Fuso Pharmaceutical Industries Ltd.
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino
  • Publication number: 20050042222
    Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.
    Type: Application
    Filed: September 21, 2004
    Publication date: February 24, 2005
    Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi
  • Publication number: 20050026232
    Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.
    Type: Application
    Filed: September 21, 2004
    Publication date: February 3, 2005
    Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi
  • Patent number: 6846912
    Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: January 25, 2005
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi
  • Publication number: 20050008645
    Abstract: Antibodies to a LAR phosphatase subunit, particularly antibodies having specificity to an intracellular domain of a phosphatase subunit, methods for generation thereof and cells producing these antibodies, and determination and examination methods of LAR/LAR derived molecules using these antibodies, as well as uses of these antibodies in diagnosis and therapy of thyroid cancer are disclosed.
    Type: Application
    Filed: June 7, 1999
    Publication date: January 13, 2005
    Inventors: Hiroshi Yamamoto, Kazutake Tsujikawa, Yukiko Uchino, Noboru Konishi